Tech Company Financing Transactions
ImmunGene Funding Round
ImmunGene, based in Thousand Oaks, secured $25 million from Burrill & Company, Anthem Capital and Canaan Partners.
Transaction Overview
Company Name
Announced On
7/11/2003
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series F
Investors
Proceeds Purpose
Proceeds from the F-2 offering will be used for commercialization of platform technologies, with the launch of a first product to monitor late stage metastatic breast cancer anticipated before the year's end. The new funds will also be used for clinical trials to expand indications in cancer and the development of products in fields outside of cancer.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
558 St. Charles Dr. 200
Thousand Oaks, CA 93012
USA
Thousand Oaks, CA 93012
USA
Phone
Website
Email Address
Overview
ImmunGene is a drug discovery and development company, developing monoclonal antibody-based therapeutics to treat cancer and other diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sanjay Khare
Chief Operating Officer
Raj Sachdev
Chief Scientific Officer
Michael Gresser
Chief Scientific Officer
Iqbal Grewal
VP - Bus. Development
Linda Pullan
Browse more venture capital transactions:
Prev: 7/10/2003: Xenogen venture capital transaction
Next: 7/14/2003: Xelerated venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on tech company VC transactions. VC investment data records on this site come from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs